Jaap Verweij

Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site

Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials

Precision Oncology: An Overview

MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours

Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era

miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas

Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure

A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study

Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients

Results of a Randomised Phase III Trial (EORTC 62012) of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide as First Line Chemotherapy for Patients with Advanced or Metastatic Soft Tissue Sarcoma: A Survival Study by the Eortc Soft Tissue and Bone Sarcoma Group